Monthly PubMed Review

Monthly PubMed Review of the Most relevant research on Lung Cancer

February 2020

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

PTGES/PGE2 signaling links immunosuppression and lung metastasis in Gprc5a-knockout mouse model. Wang T1,2, Jing B1,2, Xu D1,2, et al. Oncogene. 2020 Feb 14. doi: 10.1038/s41388-020-1207-6. [Epub ahead of print]

Tumor cell-derived angiopoietin-like protein 2 establishes a preference for glycolytic metabolism in lung cancer cells. Osumi H1,2, Horiguchi H1,3, Kadomatsu T1,4, et al. Cancer Sci. 2020 Feb 3. doi: 10.1111/cas.14337. [Epub ahead of print]

RALY may cause an aggressive biological behavior and a dismal prognosis in non-small-cell lung cancer. Song G1, Guo G1, Du T1, Li X1, Wang J1, Yan Y2, Zhao Y3. Exp Cell Res. 2020 Feb 1:111884. doi: 10.1016/j.yexcr.2020.111884. [Epub ahead of print]

SCREENING, DIAGNOSIS, BIOMARKER TESTING, AND STAGING

Evaluating Knowledge, Attitudes, and Beliefs about Lung Cancer Screening Using Crowdsourcing. Monu J1, Triplette M2, Wood DE1, Wolff EM1, Lavallee DC1, Flum DR1, Farjah F3. Chest. 2020 Feb 6. pii: S0012-3692(20)30251-8. doi: 10.1016/j.chest.2019.12.048. [Epub ahead of print]

The OaSiS trial: A hybrid type II, national cluster randomized trial to implement smoking cessation during CT screening for lung cancer. Foley KL1, Miller DP Jr2, et al. Contemp Clin Trials. 2020 Feb 19:105963. doi: 10.1016/j.cct.2020.105963. [Epub ahead of print]

Education Level Predicts Appropriate Follow-Up of Incidental Findings From Lung Cancer Screening. Kapoor S1, Deppen SA2, Paulson AB3, Haddad D4, Cook JP3, Sandler KL3. J Am Coll Radiol. 2020 Jan 10. pii: S1546-1440(19)31477-2. doi: 10.1016/j.jacr.2019.12.014. [Epub ahead of print]

Evaluating Potential Racial Inequities in Low-dose Computed Tomography Screening for Lung Cancer. Richmond J1, Mbah OM2, Dard SZ3, Jordan LC2, Cools KS4, Samuel CA5, Khan JM6, Manning MA6. J Natl Med Assoc. 2020 Feb 14. pii: S0027-9684(20)30005-5. doi: 10.1016/j.jnma.2019.10.002. [Epub ahead of print]

MicroRNA-based biomarkers for diagnosis of non-small cell lung cancer (NSCLC). Liao J1, Shen J1, Leng Q1, Qin M1, Zhan M2, Jiang F1. Thorac Cancer. 2020 Jan 28. doi: 10.1111/1759-7714.13337. [Epub ahead of print]

Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes. Tian P1,2, Liu Y1, Zeng H1, Tang Y3, Lizaso A4, Ye J4, Shao L4, Li Y5. J Cancer Res Clin Oncol. 2020 Jan 1. doi: 10.1007/s00432-019-03116-6. [Epub ahead of print]

 

NSCLC SURGERY

The association of robotic lobectomy volume and nodal upstaging in non-small cell lung cancer. Okusanya OT1, Lutfi W2, Baker N2, et al. J Robot Surg. 2020 Jan 16. doi: 10.1007/s11701-020-01044-z. [Epub ahead of print]

Electromagnetic navigational bronchoscopy-directed dye marking for locating pulmonary nodules. Wang LL1, He BF2, Cui JH2, Gao XL2, Chen PP2, Zhong WZ3, Liao RQ3, Li J4, Sun JY5. Postgrad Med J. 2020 Feb 10. pii: postgradmedj-2019-137083. doi: 10.1136/postgradmedj-2019-137083. [Epub ahead of print]

The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303). Jiang S1,2, Liang H1, Liu Z1,3, Zhao S4, Liu J1, Xie Z1, Wang W1, Zhang Y1, Han B5, He J1, Liang W1. Oncologist. 2020 Feb 20. doi: 10.1634/theoncologist.2019-0838. [Epub ahead of print]

Impact of pulmonary function on pulmonary complications after robotic-assisted thoracoscopic lobectomy. Cao C1,2, Louie BE3, Melfi F4, Veronesi G5, Razzak R3, Romano G4, Novellis P5, Ranganath NK6, Park BJ1. Eur J Cardiothorac Surg. 2020 Feb 1;57(2):338-342. doi: 10.1093/ejcts/ezz205.

NSCLC – SYSTEMIC THERAPIES (CHEMOTHERAPY, TARGETED THERAPY, AND IMMUNOTHERAPY)

Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy. Weiss JM1, Pennell N2, Deal AM1, et al. Cancer. 2020 Jan 14. doi: 10.1002/cncr.32573. [Epub ahead of print]

Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics. Arasanz H1,2, Zuazo M1, Bocanegra A1, et al. Cancers (Basel). 2020 Feb 4;12(2). pii: E344. doi: 10.3390/cancers12020344.

Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer. Sugano T1, Seike M1, Saito Y1, Thorac Cancer. 2020 Feb 25. doi: 10.1111/1759-7714.13364. [Epub ahead of print]

Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers. Tan AC1, Itchins M2,3, Khasraw M4. Int J Mol Sci. 2020 Feb 19;21(4). pii: E1416. doi: 10.3390/ijms21041416.

Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer. Hoffner B1, Leighl NB2, Davies M3. Cancer Treat Rev. 2020 Feb 4;85:101979. doi: 10.1016/j.ctrv.2020.101979. [Epub ahead of print]

CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. Felip E1, Ardizzoni A2, Ciuleanu T3, et al. Eur J Cancer. 2020 Mar;127:160-172. doi: 10.1016/j.ejca.2019.11.019. Epub 2020 Feb 3.

Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer. Tsukagoshi M1,2, Yokobori T1, Yajima T1,3, et al. Medicine (Baltimore). 2020 Feb;99(7):e19059. doi: 10.1097/MD.0000000000019059.

The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life. Park R1, Shaw JW2, Korn A3, McAuliffe J3. J Cancer Surviv. 2020 Jan 16. doi: 10.1007/s11764-020-00853-3. [Epub ahead of print]

Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era. Kehl KL1, Hassett MJ1, Schrag D1. Cancer Med. 2020 Jan 27. doi: 10.1002/cam4.2854. [Epub ahead of print]

Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589). Zhang H1,2, Qian G2, Zong D2, Fan S1, Owonikoko TK2, Ramalingam SS2, Sun SY2. Cancer. 2020 Jan 30. doi: 10.1002/cncr.32744. [Epub ahead of print]

Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis. Balasubramanian SK1, Sharma M1, Venur VA2, et al. Neuro Oncol. 2020 Feb 20;22(2):267-277. doi: 10.1093/neuonc/noz155.

A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer. Hattori Y1, Kono Y1, Itoh S1, et al. BMC Cancer. 2020 Feb 11;20(1):115. doi: 10.1186/s12885-020-6588-y.

State-of-the-Art Strategies for Targeting RET-Dependent Cancers. Subbiah V1,2,3, Yang D4, Velcheti V5, Drilon A6,7, Meric-Bernstam F1,4. J Clin Oncol. 2020 Feb 21:JCO1902551. doi: 10.1200/JCO.19.02551. [Epub ahead of print]

Phase Ib Study of Crizotinib Plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation. Patel SP1, Pakkala S2, Pennell NA3, et al. Oncologist. 2020 Feb 12. doi: 10.1634/theoncologist.2020-0034. [Epub ahead of print]

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy. Tokudome N1, Koh Y2, Akamatsu H1, et al. BMC Cancer. 2020 Feb 6;20(1):103. doi: 10.1186/s12885-020-6593-1.

NSCLC - RADIOTHERAPY

Confirmatory Analysis of QUARTZ Study Results: Survival Prolongation After Whole-brain Radiotherapy. Nieder C1,2, Dalhaug A3, Pawinski A3. Anticancer Res. 2020 Feb;40(2):977-981. doi: 10.21873/anticanres.14031.

Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients. König L1,2,3, Häfner MF4,5,6, Katayama S4,5,6, et al. Radiat Oncol. 2020 Feb 4;15(1):30. doi: 10.1186/s13014-020-1480-0.

Stereotactic ablative radiation therapy for pulmonary metastases: Improving overall survival and identifying subgroups at high risk of local failure. Pasalic D1, Lu Y2, Betancourt-Cuellar SL3, et al. Radiother Oncol. 2020 Feb 7;145:178-185. doi: 10.1016/j.radonc.2020.01.010. [Epub ahead of print]

SMALL CELL LUNG CANCER - SCLC

The impact of quantitative CT-based tumor volumetric features on the outcomes of patients with limited stage small cell lung cancer. Kamran SC1,2, Coroller T3,4, Milani N4, et al. Radiat Oncol. 2020 Jan 14;15(1):14. doi: 10.1186/s13014-020-1460-4.

High Systemic Immune-Inflammation Index (SII) Represents an Unfavorable Prognostic Factor for Small Cell Lung Cancer Treated with Etoposide and Platinum-Based Chemotherapy. Wang C1, Jin S2, Xu S3, Cao S4. Lung. 2020 Feb 3. doi: 10.1007/s00408-020-00333-6. [Epub ahead of print]

Immunotherapeutic approaches for small-cell lung cancer. Iams WT1, Porter J2, Horn L3. Nat Rev Clin Oncol. 2020 Feb 13. doi: 10.1038/s41571-019-0316-z. [Epub ahead of print]

Anlotinib in treatment of an elderly patient with recurrent advanced SCLC. Zhang Y1, Jia B1, Li J1, Xu X2. Tumori. 2020 Feb 7:300891619900673. doi: 10.1177/0300891619900673. [Epub ahead of print]

New approaches to small cell lung cancer therapy : from the laboratory to the clinic. Poirier JT1, George J2, Owonikoko TK3, et al. J Thorac Oncol. 2020 Feb 1. pii: S1556-0864(20)30056-3. doi: 10.1016/j.jtho.2020.01.016. [Epub ahead of print]

PALLIATIVE AND SUPPORTIVE CARE

Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial. Noronha V1, Bhattacharjee A2, Patil VM1, et al. Chest. 2020 Jan 17. pii: S0012-3692(20)30032-5. doi: 10.1016/j.chest.2019.11.048. [Epub ahead of print]

The association of physical function and quality of life on physical activity for non-small cell lung cancer survivors. Yoo JS1,2, Yang HC3, Lee JM3, Kim MS3, Park EC4, Chung SH5. Support Care Cancer. 2020 Jan 25. doi: 10.1007/s00520-020-05302-6. [Epub ahead of print]

COMPLEMENTARY & ALTERNATIVE THERAPY

Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial. Xiao Z1, Hu L2, Lin J1, Lu L3, Huang X1, Zhu X4, Teo C5, Lin L6. Trials. 2020 Jan 16;21(1):94. doi: 10.1186/s13063-019-3982-3.

 

MISCELLANEOUS WORKS

Precision medicine and actionable alterations in lung cancer: A single institution experience. Mambetsariev I1, Wang Y2, Chen C2, et al. PLoS One. 2020 Feb 11;15(2):e0228188. doi: 10.1371/journal.pone.0228188. eCollection 2020.

Clinical Characteristics of Patients with Cancer Presenting to the Emergency Department and their Use of Emergency Medical Service Transport. Chen B1,2, Kanaan C1, Jaiyesimi I3, Ezekwudo D3, Swor R4. Prehosp Emerg Care. 2020 Jan 21:1-16. doi: 10.1080/10903127.2020.1718258. [Epub ahead of print]

Sex-Based Disparities Among Cancer Clinical Trial Participants. Ludmir EB1, Fuller CD1, Moningi S1, et al. J Natl Cancer Inst. 2020 Feb 1;112(2):211-213. doi: 10.1093/jnci/djz154.

Social media and mobile health technology for cancer screening: a systematic review and meta-analysis protocol. Ruco A1,2, Dossa F3, Tinmouth J2,4,5, Llovet D2,5, Kishibe T6, Baxter NN MD PhD7,8. BMJ Open. 2020 Feb 5;10(2):e035411. doi: 10.1136/bmjopen-2019-035411.

Archives